[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (125)

Search Parameters:
Keywords = dermatopathology

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
3 pages, 174 KiB  
Editorial
New Insights in Paediatric Dermatopathology—2nd Edition
by Sylvie Fraitag
Dermatopathology 2024, 11(4), 374-376; https://doi.org/10.3390/dermatopathology11040040 - 17 Dec 2024
Viewed by 558
Abstract
Paediatric dermatology is still an expanding subspeciality, which is well illustrated by the growing number of books and articles that have been published on this subject in recent years [...] Full article
(This article belongs to the Special Issue New Insights in Paediatric Dermatopathology (2nd Edition))
6 pages, 2211 KiB  
Case Report
Digital Papillary Adenocarcinoma Is HPV-42-Associated and BRAFV600E Negative: Perspectives for Diagnostic Practice
by Tassilo Dege, Arno Rütten, Matthias Goebeler and Hermann Kneitz
Dermatopathology 2024, 11(4), 348-353; https://doi.org/10.3390/dermatopathology11040037 - 9 Dec 2024
Viewed by 1152
Abstract
Digital papillary adenocarcinoma (DPAC) is a rare, low-grade sweat gland carcinoma primarily found on the hands, fingers, or toes and predominantly affecting males. Distinguishing DPAC from benign sweat gland tumors can be challenging. We present the case of a 52-year-old patient with a [...] Read more.
Digital papillary adenocarcinoma (DPAC) is a rare, low-grade sweat gland carcinoma primarily found on the hands, fingers, or toes and predominantly affecting males. Distinguishing DPAC from benign sweat gland tumors can be challenging. We present the case of a 52-year-old patient with a progressive tumor on the finger initially misdiagnosed as a viral wart. Histological examination revealed a cytologically basophilic sweat gland tumor with tubular structures, papillary protrusions, and a characteristic immunohistochemical staining pattern for CK 7 and Actin. HPV-42 positivity and molecular analysis confirmed the diagnosis of DPAC. HPV-42 has been strongly associated with DPAC. Additionally, p16 positivity and BRAFV600E negativity were observed. These findings aid in the differential diagnosis of acral sweat gland tumors and guide clinical management, including with respect to the potential for recurrence and metastasis. Full article
(This article belongs to the Section Clinico-Pathological Correlation in Dermatopathology)
Show Figures

Figure 1

Figure 1
<p>(<b>A</b>,<b>B</b>): Left middle finger distal phalanx with a centrally ulcerated, skin-colored tumor measuring 1.8 cm × 1.1 cm. (<b>C</b>–<b>E</b>): Hemotoxylin–Eosin stain showing an adnexal tumor (<b>C</b>, overview, 25×) with solid proliferations of pleomorphic, basophilic cells (<b>D</b>, 40×) and tubular structures with signs of decapitation secretion (<b>E</b>, 40×).</p>
Full article ">Figure 2
<p>(<b>A</b>–<b>C</b>): Hemotoxylin–Eosin stain (<b>A</b>, 40×), correlated with immunostains, showing tumor cell complexes with heterogeneous expression of CK7 (*) (<b>B</b>, 40×). An outer actin-positive (+) myoepithelial layer (<b>C</b>, 40×) surrounds tumor cells. (<b>D</b>): Sequence of tumor DNA matching HPV-42.</p>
Full article ">Figure 3
<p>(<b>A</b>): Tumor cells stain strongly positive for p16. (<b>B</b>): Tumor cells immunohistochemically negative for BRAFV600E.</p>
Full article ">
9 pages, 4793 KiB  
Review
“Chasing Rainbows” Beyond Kaposi Sarcoma’s Dermoscopy: A Mini-Review
by Emmanouil Karampinis, Olga Toli, Georgia Pappa, Anna Vardiampasi, Melpomeni Theofili, Efterpi Zafiriou, Mattheos Bobos, Aimilios Lallas, Elizabeth Lazaridou, Biswanath Behera and Zoe Apalla
Dermatopathology 2024, 11(4), 333-341; https://doi.org/10.3390/dermatopathology11040035 - 25 Nov 2024
Cited by 1 | Viewed by 875
Abstract
The dermoscopic rainbow pattern (RP), also known as polychromatic pattern, is characterized by a multicolored appearance, resulting from the dispersion of polarized light as it penetrates various tissue components. Its separation into different wavelengths occurs according to the physics principles of scattering, absorption, [...] Read more.
The dermoscopic rainbow pattern (RP), also known as polychromatic pattern, is characterized by a multicolored appearance, resulting from the dispersion of polarized light as it penetrates various tissue components. Its separation into different wavelengths occurs according to the physics principles of scattering, absorption, and interference of light, creating the optical effect of RP. Even though the RP is regarded as a highly specific dermoscopic indicator of Kaposi’s sarcoma, in the medical literature, it has also been documented as an atypical dermoscopic finding of other non-Kaposi skin entities. We aim to present two distinct cases—a pigmented basal cell carcinoma (pBCC) and an aneurysmatic dermatofibroma—that exhibited RP in dermoscopy and to conduct a thorough review of skin conditions that display RP, revealing any predisposing factors that could increase the likelihood of its occurrence in certain lesions. We identified 33 case reports and large-scale studies with diverse entities characterized by the presence of RP, including skin cancers (Merkel cell carcinoma, BCC, melanoma, etc.), adnexal tumors, special types of nevi (blue, deep penetrating), vascular lesions (acroangiodermatitis, strawberry angioma, angiokeratoma, aneurismatic dermatofibromas, etc.), granulation tissue, hypertrophic scars and fibrous lesions, skin infections (sporotrichosis and cutaneous leishmaniasis), and inflammatory dermatoses (lichen simplex and stasis dermatitis). According to our results, the majority of the lesions exhibiting the RP were located on the extremities. Identified precipitating factors included the nodular shape, lesion composition and vascularization, skin pigmentation, and lesions’ depth and thickness. These parameters lead to increased scattering and interference of light, producing a spectrum of colors that resemble a rainbow. Full article
(This article belongs to the Special Issue Associations between Dermoscopy and Dermatopathology)
Show Figures

Figure 1

Figure 1
<p>Dermoscopic (<b>A</b>) and histopathology (<b>B</b>) (H&amp;E, 4Χ magnification) images of a nodular pBCC, which displayed PR during the dermoscopy examination.</p>
Full article ">Figure 2
<p>Dermoscopy of a hemosiderotic dermatofibroma, displaying RP in the center of the lesion: (<b>A</b>) histopathology of the tumor showed dense fibrohistiocytic proliferation, scattered hemosiderin deposition, and a vessel filled with erythrocytes (<b>B</b>) (H&amp;E 20X magnification).</p>
Full article ">Figure 3
<p>(<b>A</b>) Dermoscopy of Lichen planus in an Indian patient exhibiting PR (blue arrow) and peripheral pigmentation. (<b>B</b>) Dermoscopy of a post-burn hypertrophic scar presenting multiple iridescent areas.</p>
Full article ">
15 pages, 6196 KiB  
Article
Image-Guided Radiation Therapy Is Equally Effective for Basal and Squamous Cell Carcinoma
by Erin M. McClure, Clay J. Cockerell, Stephen Hammond, Evelyn S. Marienberg, Bobby N. Koneru, Jon Ward and Jeffrey B. Stricker
Dermatopathology 2024, 11(4), 315-329; https://doi.org/10.3390/dermatopathology11040033 - 19 Nov 2024
Viewed by 690
Abstract
Non-melanoma skin cancers (NMSCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are highly prevalent and a significant cause of morbidity. Image-guided superficial radiation therapy (IGSRT) uses integrated high-resolution dermal ultrasound to improve lesion visualization, but it is unknown whether efficacy [...] Read more.
Non-melanoma skin cancers (NMSCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are highly prevalent and a significant cause of morbidity. Image-guided superficial radiation therapy (IGSRT) uses integrated high-resolution dermal ultrasound to improve lesion visualization, but it is unknown whether efficacy varies by histology. This large retrospective cohort study was conducted to determine the effect of tumor histology on freedom from recurrence in 20,069 biopsy-proven NMSC lesions treated with IGSRT, including 9928 BCCs (49.5%), 5294 SCCs (26.4%), 4648 SCCIS cases (23.2%), and 199 lesions with ≥2 NMSCs (1.0%). Freedom from recurrence at 2, 4, and 6 years was 99.60%, 99.45%, and 99.45% in BCC; 99.58%, 99.49%, and 99.49% in SCC; and 99.96%, 99.80%, and 99.80% in SCCIS. Freedom from recurrence at 2, 4, and 6 years following IGSRT did not differ significantly comparing BCC vs. non-BCC or SCC vs. non-SCC but were slightly lower among SCCIS vs. non-SCCIS (p = 0.002). There were no significant differences in freedom from recurrence when stratifying lesions by histologic subtype. This study demonstrates that there is no significant effect of histology on freedom from recurrence in IGSRT-treated NMSC except in SCCIS. These findings support IGSRT as a first-line therapeutic option for NMSC regardless of histology. Full article
Show Figures

Figure 1

Figure 1
<p>Histological examples of nodular BCC (<b>A</b>), superficial BCC (<b>B</b>), squamous differentiation BCC (<b>C</b>), infiltrative (<b>D</b>), and morpheaform BCC (<b>E</b>).</p>
Full article ">Figure 2
<p>Histological examples of SCCIS (<b>A</b>) and well-differentiated SCC (<b>B</b>).</p>
Full article ">Figure 3
<p>Freedom from recurrence over time of non-melanoma skin cancers treated with image-guided superficial radiation therapy in patients with basal cell carcinoma versus non-basal cell carcinoma skin cancers.</p>
Full article ">Figure 4
<p>Freedom from recurrence over time of non-melanoma skin cancers treated with image-guided superficial radiation therapy in patients with squamous cell carcinoma versus non-squamous cell carcinoma skin cancers.</p>
Full article ">Figure 5
<p>Freedom from recurrence over time of non-melanoma skin cancers treated with image-guided superficial radiation therapy in patients with squamous cell carcinoma in situ versus non-squamous cell carcinoma in situ skin cancers.</p>
Full article ">Figure 6
<p>Freedom from recurrence over time of basal cell carcinoma subtypes treated with image-guided superficial radiation therapy.</p>
Full article ">Figure 7
<p>Freedom from recurrence over time of well-differentiated squamous cell carcinoma treated with image-guided superficial radiation therapy.</p>
Full article ">Figure 8
<p>Case 1. Complete response of nodular basal cell carcinoma to IGSRT. Top panels demonstrate the ultrasound images of the IGSRT device before treatment (simulation), mid-treatment, and at final follow-up. The bottom panels demonstrate the clinical response at these same time points.</p>
Full article ">Figure 9
<p>Case 2. Complete response of squamous cell carcinoma to IGSRT. Top panels demonstrate the ultrasound images of the IGSRT device before treatment (simulation), mid-treatment, and at final follow-up. The bottom panels demonstrate the clinical response at these same time points.</p>
Full article ">Figure 10
<p>Recurrence of nodular basal cell carcinoma after IGSRT treatment. Top panels demonstrate the ultrasound images of the IGSRT device before treatment (simulation), mid treatment, and at final follow-up. The bottom panels demonstrate the clinical response at these same time points.</p>
Full article ">
14 pages, 1114 KiB  
Review
Advanced Artificial Intelligence Techniques for Comprehensive Dermatological Image Analysis and Diagnosis
by Serra Aksoy, Pinar Demircioglu and Ismail Bogrekci
Dermato 2024, 4(4), 173-186; https://doi.org/10.3390/dermato4040015 - 16 Nov 2024
Cited by 1 | Viewed by 785
Abstract
With the growing complexity of skin disorders and the challenges of traditional diagnostic methods, AI offers exciting new solutions that can enhance the accuracy and efficiency of dermatological assessments. Reflectance Confocal Microscopy (RCM) stands out as a non-invasive imaging technique that delivers detailed [...] Read more.
With the growing complexity of skin disorders and the challenges of traditional diagnostic methods, AI offers exciting new solutions that can enhance the accuracy and efficiency of dermatological assessments. Reflectance Confocal Microscopy (RCM) stands out as a non-invasive imaging technique that delivers detailed views of the skin at the cellular level, proving its immense value in dermatology. The manual analysis of RCM images, however, tends to be slow and inconsistent. By combining artificial intelligence (AI) with RCM, this approach introduces a transformative shift toward precise, data-driven dermatopathology, supporting more accurate patient stratification, tailored treatments, and enhanced dermatological care. Advancements in AI are set to revolutionize this process. This paper explores how AI, particularly Convolutional Neural Networks (CNNs), can enhance RCM image analysis, emphasizing machine learning (ML) and deep learning (DL) methods that improve diagnostic accuracy and efficiency. The discussion highlights AI’s role in identifying and classifying skin conditions, offering benefits such as a greater consistency and a reduced strain on healthcare professionals. Furthermore, the paper explores AI integration into dermatological practices, addressing current challenges and future possibilities. The synergy between AI and RCM holds the potential to significantly advance skin disease diagnosis, ultimately leading to better therapeutic personalization and comprehensive dermatological care. Full article
(This article belongs to the Special Issue Reviews in Dermatology: Current Advances and Future Directions)
Show Figures

Figure 1

Figure 1
<p>The principles of Reflectance Confocal Microscopy [<a href="#B27-dermato-04-00015" class="html-bibr">27</a>].</p>
Full article ">Figure 2
<p>VivaNet<sup>®</sup> workflow: image acquisition site to remote reading rtation for RCM [<a href="#B36-dermato-04-00015" class="html-bibr">36</a>].</p>
Full article ">Figure 3
<p>In vivo confocal laser scanning microscope (830 nm)—the wide-probe confocal device (VivaScope<sup>®</sup>1500; image courtesy—VivaScope GmbH, Munich, Germany) [<a href="#B37-dermato-04-00015" class="html-bibr">37</a>].</p>
Full article ">
16 pages, 2330 KiB  
Article
Clinical Utility of a Digital Dermoscopy Image-Based Artificial Intelligence Device in the Diagnosis and Management of Skin Cancer by Dermatologists
by Alexander M. Witkowski, Joshua Burshtein, Michael Christopher, Clay Cockerell, Lilia Correa, David Cotter, Darrell L. Ellis, Aaron S. Farberg, Jane M. Grant-Kels, Teri M. Greiling, James M. Grichnik, Sancy A. Leachman, Anthony Linfante, Ashfaq Marghoob, Etan Marks, Khoa Nguyen, Alex G. Ortega-Loayza, Gyorgy Paragh, Giovanni Pellacani, Harold Rabinovitz, Darrell Rigel, Daniel M. Siegel, Eingun James Song, David Swanson, David Trask and Joanna Ludzikadd Show full author list remove Hide full author list
Cancers 2024, 16(21), 3592; https://doi.org/10.3390/cancers16213592 - 24 Oct 2024
Viewed by 1202
Abstract
Background: Patients with skin lesions suspicious for skin cancer or atypical melanocytic nevi of uncertain malignant potential often present to dermatologists, who may have variable dermoscopy triage clinical experience. Objective: To evaluate the clinical utility of a digital dermoscopy image-based artificial intelligence algorithm [...] Read more.
Background: Patients with skin lesions suspicious for skin cancer or atypical melanocytic nevi of uncertain malignant potential often present to dermatologists, who may have variable dermoscopy triage clinical experience. Objective: To evaluate the clinical utility of a digital dermoscopy image-based artificial intelligence algorithm (DDI-AI device) on the diagnosis and management of skin cancers by dermatologists. Methods: Thirty-six United States board-certified dermatologists evaluated 50 clinical images and 50 digital dermoscopy images of the same skin lesions (25 malignant and 25 benign), first without and then with knowledge of the DDI-AI device output. Participants indicated whether they thought the lesion was likely benign (unremarkable) or malignant (suspicious). Results: The management sensitivity of dermatologists using the DDI-AI device was 91.1%, compared to 84.3% with DDI, and 70.0% with clinical images. The management specificity was 71.0%, compared to 68.4% and 64.9%, respectively. The diagnostic sensitivity of dermatologists using the DDI-AI device was 86.1%, compared to 78.8% with DDI, and 63.4% with clinical images. Diagnostic specificity using the DDI-AI device increased to 80.7%, compared to 75.9% and 73.6%, respectively. Conclusion: The use of the DDI-AI device may quickly, safely, and effectively improve dermoscopy performance, skin cancer diagnosis, and management when used by dermatologists, independent of training and experience. Full article
(This article belongs to the Special Issue Advances in Oncological Imaging)
Show Figures

Figure 1

Figure 1
<p>Current DDI-AI device outputs and labeling (Apple iPhone 15 PRO: (<b>A</b>,<b>C</b>); Samsung A14: (<b>B</b>)). (<b>A</b>) SUSPICIOUS (melanoma in situ): Positive (MD3PC) with moderate to high concern for malignancy. Recommended action: Additional evaluation is recommended, as determined appropriate by the medical professional. For a dermatologist, this may be a biopsy, or referral to another dermatologist for a second opinion. If the dermatologist chooses not to biopsy, it is strongly recommended that they document the DDI by uploading the DDI-AI output result to the patient electronic medical record (EMR). For patient safety, in the setting of biopsy avoidance, the DDI-AI recommends the user to complete a DDI spot check follow-up within a 3-month period. The dermatologist should also explain the patient to communicate earlier in the event a change is observed in mole size, shape, or color at any time during the 3-month period. (<b>B</b>) UNREMARKABLE (sebaceous hyperplasia): No immediate concern, limited or no positive MD3PC, with low concern for malignancy. Recommended action: The dermatologist should consider documenting the DDI by uploading the DDI-AI output result to the patient EMR. Recommend a DDI spot check follow-up within a 6-month period. The clinician should also explain the patient to communicate earlier in the event a change is observed in mole size, shape, or color at any time. (<b>C</b>) ERROR (dermatofibroma): The image does not meet DDI-AI technical inclusion criteria and an assessment of the uploaded DDI cannot be made. This result may be returned to the user when the image is not the right sort of item, inadequate immersion oil is used, or when the image quality is insufficient. Recommended action: If an “ERROR” result is obtained, the labeling information explains how to properly retake DDI with a maximum of three attempts per target lesion. If there are three failed consecutive attempts on the same TSLC, DDI-AI labeling instructs the user to not consider the DDI-AI output in their decision-making process and use their independent clinical judgement. Disclaimer: The use of DDI-AI is not intended to issue a final diagnosis and is not a total body mole scanner.</p>
Full article ">Figure 2
<p>DDI-AI device outputs. (<b>A</b>) Clinical image of a melanoma (black arrow). (<b>B</b>) DDI-AI device suspicious output. (<b>C</b>–<b>E</b>) DDI-AI device transparent heatmap outputs based on the possible presence of modified dermoscopy three-point checklist criteria (MD3PC), presented individually to the user. (<b>F</b>) Clinical image of a basal cell carcinoma (black arrow). (<b>G</b>) DDI-AI device suspicious output. (<b>H</b>–<b>J</b>) DDI-AI device transparent heatmap outputs.</p>
Full article ">Figure 3
<p>The receiver operator characteristics (ROC) for dermatologist (<b>A</b>) diagnostic sensitivity and specificity, (<b>B</b>) management sensitivity and specificity, both adjusted for participant confidence in their decision (none, slight, moderate, high), and (<b>C</b>) MD3PC-specific features for detecting malignancy. Red line (dermatologists using DDI evaluated with clinical experience), blue line (same dermatologists using the DDI-AI device output), and green line (dermatologists using the DDI-AI heatmaps).</p>
Full article ">
10 pages, 1423 KiB  
Article
Expression of TRPS1 in Metastatic Tumors of the Skin: An Immunohistochemical Study of 72 Cases
by Kassiani Boulogeorgou, Christos Topalidis, Triantafyllia Koletsa, Georgia Karayannopoulou and Jean Kanitakis
Dermatopathology 2024, 11(4), 293-302; https://doi.org/10.3390/dermatopathology11040031 - 23 Oct 2024
Viewed by 1003
Abstract
TRPS1 (Tricho-rhino-phalangeal syndrome 1) is a GATA transcriptional activator gene encoding for a protein used as a sensitive immunohistochemical marker of breast carcinomas. In dermatopathology, TRPS1 is used as a marker of mammary and extramammary Paget’s disease and is also expressed by a [...] Read more.
TRPS1 (Tricho-rhino-phalangeal syndrome 1) is a GATA transcriptional activator gene encoding for a protein used as a sensitive immunohistochemical marker of breast carcinomas. In dermatopathology, TRPS1 is used as a marker of mammary and extramammary Paget’s disease and is also expressed by a variety of primary cutaneous tumors, mostly of adnexal origin. So far, very limited data exist on the expression of TRPS1 in metastatic skin tumors. We studied the immunohistochemical expression of TRPS1 in 72 cutaneous metastatic tumors from the breast (n: 19) and other origins (n: 53) in order to assess its diagnostic usefulness. The intensity of TRPS1 immunostaining was expressed as a histoscore: the product of the percentage of positive cells (scored semi-quantitatively 0–4) and the staining intensity (scored 0–3). In normal skin, nuclear TRPS1 expression was predominantly observed in cells of adnexal structures (pilosebaceous follicles and sweat glands). Eighteen (18/19, 94.7%) metastatic breast carcinomas showed diffuse and strong TRPS1 positivity (histoscore 12). Lower reactivity was found in some other metastases, including from the lung (11/22), the female genital tract (3/4), and the kidney (2/4), whereas most (20/22) metastases from the digestive system and peritoneum, along with a case of metastatic prostate carcinoma, were negative. These results suggest that a high histoscore for TRPS1 is in favor of the mammary origin of metastatic cutaneous carcinoma. Although TRPS1 is not absolutely specific or sensitive to a particular primary, we consider that it can be added to a panel of other markers when investigating the origin of a cutaneous metastasis, namely when this is the first manifestation of the neoplastic disease. Full article
(This article belongs to the Section Experimental Dermatopathology)
Show Figures

Figure 1

Figure 1
<p>Nuclear TRPS1 expression in normal skin. TRPS1 is strongly expressed in a sweat gland coil, consisting of a secretory and an excretory segment (<b>A</b>). TRPS1 is expressed by cells of the hair follicle sheath (<b>B</b>), the sebaceous gland (<b>C</b>), and fibroblasts of the hair bulb (<b>D</b>). TRPS1 expression allows us to visualize the intraepidermal parts of the sweat ducts/acrosyringia (<b>E</b>) and the hair follicles (<b>F</b>). Immunoperoxidase revealed with diaminobenzidine, counterstaining with Mayer’s hematoxylin.</p>
Full article ">Figure 2
<p>Expression of TRPS1 by metastatic skin tumors. Diffuse and strong TRPS1 expression (histoscore 12) in a metastatic breast carcinoma (<b>A</b>) and a pulmonary squamous cell carcinoma (<b>B</b>). Note the weak TRPS1 expression by epidermal keratinocytes. Variable, weaker TRPS1 expression is seen in cases of metastases from renal cell carcinoma ((<b>C</b>), histoscore 8), ovarian carcinoma ((<b>D</b>), histoscore 8), and lung carcinoma ((<b>E</b>), histoscore 3). (<b>F</b>): TRPS1-negative colon adenocarcinoma (histoscore 0). Immunoperoxidase revealed with diaminobenzidine, counterstaining with Mayer’s hematoxylin.</p>
Full article ">
14 pages, 1374 KiB  
Review
Keratoacanthoma versus Squamous-Cell Carcinoma: Histopathological Features and Molecular Markers
by Hisham F. Bahmad, Kalin Stoyanov, Teresita Mendez, Sally Trinh, Kristy Terp, Linda Qian and John Alexis
Dermatopathology 2024, 11(4), 272-285; https://doi.org/10.3390/dermatopathology11040029 - 8 Oct 2024
Viewed by 1694
Abstract
Considerable controversy exists within the field of dermatopathology in differentiating keratoacanthoma (KA) from squamous-cell carcinoma (SCC). KAs are rapidly growing, benign squamous tumors that are typically well differentiated. This controversy stems from the diverging perspectives on the management, classification, and diagnosis of each [...] Read more.
Considerable controversy exists within the field of dermatopathology in differentiating keratoacanthoma (KA) from squamous-cell carcinoma (SCC). KAs are rapidly growing, benign squamous tumors that are typically well differentiated. This controversy stems from the diverging perspectives on the management, classification, and diagnosis of each entity. Many believe that KAs are benign neoplasms in which intervention may be unnecessary since they are self-limiting and resolve on their own. On the other hand, SCC needs to be treated, as it carries significant morbidity and mortality risks. Early diagnosis and treatment are vital to prevent serious consequences of SCC. Nevertheless, KAs may resemble SCC grossly and microscopically. Various ancillary tests, including immunohistochemical (IHC) staining, have been proposed to differentiate between these entities, though mixed patterns of expression can limit the diagnostic utility of these techniques. Research into this topic is ongoing, with newer genetic and molecular findings illuminating the previously difficult-to-understand aspects of KA and increasing our understanding of this entity. In this review, KA and SCC will be compared along the lines of histological features, genetic, immune, and molecular markers, differential diagnosis, and management to clarify the similarities, differences, and misconceptions about both entities. Full article
Show Figures

Figure 1

Figure 1
<p>Histopathologic features of keratoacanthoma. <span class="html-italic">Developing keratoacanthoma</span> includes two phases: the proliferation phase (where the tumor is small, primarily solid, with distinct infundibulocystic structures that have not yet coalesced into a central keratin plug, containing islands of laminated keratin with a ground-glass appearance) and the maturation phase (which demonstrates an exo–endophytic squamous proliferation with a central keratin plug, overhanging epithelial lips, and compact keratinization). <span class="html-italic">Regressing keratoacanthoma</span> shows a “hollowing out” lesion with loss of central keratin plug, perilesional lymphohistiocytic infiltrate, and increasing fibrosis (H&amp;E; magnification: (<b>A</b>,<b>C</b>): 40×, (<b>B</b>,<b>D</b>): 100×).</p>
Full article ">Figure 2
<p>Schematic drawing of a skin tumor being sampled to make a histopathologic diagnosis of keratoacanthoma versus squamous-cell carcinoma.</p>
Full article ">
6 pages, 3271 KiB  
Clinicopathological Challenge
A Rapidly Growing Nodule on the Eyebrow of a Pediatric Patient
by Italo Francesco Aromolo, Michela Brena, Nicola Adriano Monzani, Fabio Caviggioli, Emilio Berti, Donata Micello and Riccardo Cavalli
Dermatopathology 2024, 11(4), 266-271; https://doi.org/10.3390/dermatopathology11040028 - 30 Sep 2024
Viewed by 992
Abstract
A 11-year-old Caucasian girl presented to our Dermatology Unit with a 2-month history of an erythematous nodule, localized to the medial portion of her left eyebrow, rapidly growing in the two weeks before presentation. The histopathological examination revealed a dermal multi-nodular epithelial neoplasm [...] Read more.
A 11-year-old Caucasian girl presented to our Dermatology Unit with a 2-month history of an erythematous nodule, localized to the medial portion of her left eyebrow, rapidly growing in the two weeks before presentation. The histopathological examination revealed a dermal multi-nodular epithelial neoplasm composed of clear cells, squamous cells, and glandular cells, characterized by cytologic atypia, high mitotic activity, and an infiltrative deep growth pattern. The immunohistochemical profile of the lesion was as follows: CKAE1/AE3+, EMA+, CK8/18+, CK7+, CK19+, AR negative, p63 focally +, Ki67 25%, rare cells GCDFP15+, p53+. Full article
Show Figures

Figure 1

Figure 1
<p>Erythematous nodule at the medial root of the left eyebrow arch (<b>a</b>). A dermal multi-nodular epithelial neoplasm (H&amp;E, 0.5×) (<b>b</b>). An infiltrative growth pattern with clear cells and duct-like glandular structures (<b>c</b>) and squamous cells with hemorrhages (<b>d</b>) (H&amp;E, 12× and 10×).</p>
Full article ">Figure 2
<p>Infiltrative neoplastic growth composed of atypical cells, sometimes lining tubular structures. Areas of squamoid differentiation are appreciable (H&amp;E, 16×) (<b>a</b>). A detail where clear cells are appreciable (H&amp;E, 20×) (<b>b</b>). EMA staining highlights ductal structures (EMA, 12×) (<b>c</b>). Ki67 is about 25% in the “hotspot” areas (Ki67, 15×) (<b>d</b>).</p>
Full article ">Figure 3
<p>CK7 is positive (<b>a</b>) and CK8/18 is also positive (<b>b</b>), confirming adnexal differentiation. p63 is positive only in areas with squamoid differentiation but negative in most of the neoplasm (<b>c</b>). The androgen receptor is negative (<b>d</b>). Magnification: (<b>a</b>) 1×; (<b>b</b>) 5×; (<b>c</b>) 2.5×; (<b>d</b>) 2.5×.</p>
Full article ">
13 pages, 271 KiB  
Review
Ethical Issues Regarding Dermatopathology Care for Service-Members: A Review
by Samir Kamat, Ross O’Hagan, Catherine Brahe, Curtis L. Hardy, Vikas Shrivastava, Jane M. Grant-Kels and Angela M. Crotty
Dermatopathology 2024, 11(4), 253-265; https://doi.org/10.3390/dermatopathology11040027 - 24 Sep 2024
Viewed by 971
Abstract
Dermatologic care within the military faces unique ethical challenges. Service members are stationed across nationally and globally diverse settings, and therefore, dermatologic care rendered ranges from within resource-rich, advanced military medical treatment facilities to austere, resource-limited, deployed field environments. Additionally, military service members [...] Read more.
Dermatologic care within the military faces unique ethical challenges. Service members are stationed across nationally and globally diverse settings, and therefore, dermatologic care rendered ranges from within resource-rich, advanced military medical treatment facilities to austere, resource-limited, deployed field environments. Additionally, military service members are often at unique risk for dermatologic disease, given occupational, environmental, and geographic exposures not commonly faced by their civilian counterparts. This review explores topics in dermatoethics via case analyses of ethical considerations within the scope of dermatologic care for military service members. Full article
1 pages, 135 KiB  
Editorial
Clinicopathological Challenge: A New Article Type in Dermatopathology
by Gürkan Kaya
Dermatopathology 2024, 11(3), 238; https://doi.org/10.3390/dermatopathology11030025 - 14 Aug 2024
Viewed by 1145
Abstract
As the Editor-in-Chief of Dermatopathology, I have the great pleasure of announcing a new article type: “Clinicopathological Challenge” [...] Full article
8 pages, 3646 KiB  
Perspective
A Review of Atypical Cutaneous Histological Manifestations of Herpes Zoster
by Maged Daruish, Gerardo Cazzato, Dorota Markiewicz, Saleem Taibjee, Francesco Fortarezza and Eduardo Calonje
Viruses 2024, 16(7), 1035; https://doi.org/10.3390/v16071035 - 27 Jun 2024
Viewed by 1286
Abstract
The clinical and histopathological features of herpes zoster (HZ) are usually straightforward. Atypical histological presentations, in the absence of the classical viral cytopathic changes, are well documented and can make the diagnosis of HZ extremely difficult. Herein, we review the existing literature on [...] Read more.
The clinical and histopathological features of herpes zoster (HZ) are usually straightforward. Atypical histological presentations, in the absence of the classical viral cytopathic changes, are well documented and can make the diagnosis of HZ extremely difficult. Herein, we review the existing literature on atypical cutaneous histological manifestations of the disease, with emphasis on the subtle clues, use of immunohistochemistry, and potential pitfalls. Full article
(This article belongs to the Section General Virology)
Show Figures

Figure 1

Figure 1
<p><b>Typical histology of cutaneous VZV infection:</b> (<b>A</b>,<b>B</b>) Suprabasal separation consequent to ballooning, reticular degeneration, and keratinocytes necrosis; hematoxylin and eosin (H&amp;E) ×10 and ×100. (<b>C</b>) Steel grey nuclei with peripheral condensation of chromatin can be seen; (H&amp;E) ×200. (<b>D</b>) Multinucleated cells are common; (H&amp;E) ×200.</p>
Full article ">Figure 2
<p><b>Subtle changes in HZ:</b> (<b>A</b>,<b>B</b>) Interface vacuolar damage, erythrocytes extravasation, and perineural inflammation may be the only pathological features identified; (H&amp;E) ×200.</p>
Full article ">Figure 3
<p>IHC for VZV shows diffuse and strong membranous staining in active lesions ×200.</p>
Full article ">Figure 4
<p>(<b>A</b>) Necrotizing VZV folliculitis; (H&amp;E) ×200. (<b>B</b>) Nuclear staining for VZV IHC in follicular epithelial remnants; (H&amp;E) ×200.</p>
Full article ">Figure 5
<p>(<b>A</b>) Dense perifollicular lymphoid cell infiltrate in the absence of viral cytopathic changes in the epidermis and follicular epithelium; (H&amp;E) ×100. (<b>B</b>) The lymphocytes are T-cells as confirmed by CD3 diffuse staining ×100. Necrosis and cytopathic changes may be found after numerous serial sections are examined.</p>
Full article ">Figure 6
<p>A rare clinical presentation of bilateral vasculitic HZ in an immunosuppressed patient. He also had radiculopathy with leg weakness (mimicking Guillain–Barré neuropathy). This all resolved with acyclovir.</p>
Full article ">Figure 7
<p>Leucocytoclastic vasculitis underlying a blister with VZV cytopathic changes; (H&amp;E) ×200.</p>
Full article ">
13 pages, 1536 KiB  
Article
Gene Expression Profile of Benign, Intermediate, and Malignant Spitz and Spitzoid Melanocytic Lesions
by Alessio Giubellino, Yuyu He, Sarah A. Munro, Yan Zhou, Kyu Young Song, Jose A. Plaza, Carlos A. Torres-Cabala and Andrew C. Nelson
Cancers 2024, 16(10), 1798; https://doi.org/10.3390/cancers16101798 - 8 May 2024
Viewed by 1216
Abstract
Spitz and Spitzoid lesions represent one of the most challenging melanocytic neoplasms in dermatopathology. Nosologic classification has been more recently improved by the discovery of novel molecular drivers, particularly translocations. In the current study, we aimed to use an unbiased approach to explore [...] Read more.
Spitz and Spitzoid lesions represent one of the most challenging melanocytic neoplasms in dermatopathology. Nosologic classification has been more recently improved by the discovery of novel molecular drivers, particularly translocations. In the current study, we aimed to use an unbiased approach to explore the gene expression profile of a group of melanocytic Spitz and Spitzoid melanocytic lesions ranging from benign lesions to melanoma, including intermediate lesions such as SPARK nevi and atypical Spitz tumors/melanocytomas. Using unsupervised analysis of gene expression data, we found some distinct hierarchical clusters of lesions, including groups characterized by ALK and NTRK translocations. Few non-ALK translocated tumors demonstrated increased ALK expression, confirmed by immunohistochemistry. Spitz tumors with overlapping features of dysplastic nevi, so-called SPARK nevi, appear to have a common gene expression profile by hierarchical clustering. Finally, weighted gene correlation network analysis identified gene modules variably regulated in subtypes of these cases. Thus, gene expression profiling of Spitz and Spitzoid lesions represents a viable instrument for the characterization of these lesions. Full article
(This article belongs to the Special Issue Melanoma: Pathology and Translational Research)
Show Figures

Figure 1

Figure 1
<p>Representative histopathology pictures of selected cases from each category. (<b>A</b>) Compound Spitz nevus; (<b>B</b>) Reed nevus with NTRK-MYO5A translocation; (<b>C</b>) ALK-fusion Spitz nevus (TMP3-ALK); (<b>D</b>) “Spark” nevus; (<b>E</b>) Atypical Spitz tumor; (<b>F</b>) Spitzoid melanoma. Low power images magnification is at 4× and high power images are at 20× magnification.</p>
Full article ">Figure 2
<p>Hierarchical distance-based clustering of samples using gene expression data with the hclust function in R. Clusters for ALK-translocated tumors, SPARK nevi, and Reed nevi are highlighted in red, purple, and blue, respectively.</p>
Full article ">Figure 3
<p>WGCNA module eigengene plots are separated by the three sample groupings: SPARK group (1), Reed nevi group (2), and ALK group (3).</p>
Full article ">Figure 3 Cont.
<p>WGCNA module eigengene plots are separated by the three sample groupings: SPARK group (1), Reed nevi group (2), and ALK group (3).</p>
Full article ">
22 pages, 3013 KiB  
Article
JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines
by Enrica Flori, Alessia Cavallo, Sarah Mosca, Daniela Kovacs, Carlo Cota, Marco Zaccarini, Anna Di Nardo, Grazia Bottillo, Miriam Maiellaro, Emanuela Camera and Giorgia Cardinali
Cells 2024, 13(9), 760; https://doi.org/10.3390/cells13090760 - 29 Apr 2024
Viewed by 2031
Abstract
Derangement of the epidermal barrier lipids and dysregulated immune responses are key pathogenic features of atopic dermatitis (AD). The Th2-type cytokines interleukin IL-4 and IL-13 play a prominent role in AD by activating the Janus Kinase/Signal Transduction and Activator of Transcription (JAK/STAT) intracellular [...] Read more.
Derangement of the epidermal barrier lipids and dysregulated immune responses are key pathogenic features of atopic dermatitis (AD). The Th2-type cytokines interleukin IL-4 and IL-13 play a prominent role in AD by activating the Janus Kinase/Signal Transduction and Activator of Transcription (JAK/STAT) intracellular signaling axis. This study aimed to investigate the role of JAK/STAT in the lipid perturbations induced by Th2 signaling in 3D epidermal equivalents. Tofacitinib, a low-molecular-mass JAK inhibitor, was used to screen for JAK/STAT-mediated deregulation of lipid metabolism. Th2 cytokines decreased the expression of elongases 1, 3, and 4 and serine-palmitoyl-transferase and increased that of sphingolipid delta(4)-desaturase and carbonic anhydrase 2. Th2 cytokines inhibited the synthesis of palmitoleic acid and caused depletion of triglycerides, in association with altered phosphatidylcholine profiles and fatty acid (FA) metabolism. Overall, the ceramide profiles were minimally affected. Except for most sphingolipids and very-long-chain FAs, the effects of Th2 on lipid pathways were reversed by co-treatment with tofacitinib. An increase in the mRNA levels of CPT1A and ACAT1, reduced by tofacitinib, suggests that Th2 cytokines promote FA beta-oxidation. In conclusion, pharmacological inhibition of JAK/STAT activation prevents the lipid disruption caused by the halted homeostasis of FA metabolism. Full article
Show Figures

Figure 1

Figure 1
<p>Effects of JAK/STAT inhibition by tofacitinib on the Th2-mediated changes in epidermal morphology and barrier protein/enzyme expression. (<b>A</b>) Hematoxylin and eosin staining (H&amp;E) of paraffin-embedded 3D HEEs treated with vehicle Th2 (IL-4 and IL-13), and tofacitinib. Histological analysis of Th2-treated HEEs showed characteristic AD morphologic features such as epidermal thickening and increased spaces between adjacent keratinocytes (arrows). Scale bars: 50 µm, 20 µm. (<b>B</b>) Quantitative analysis of epidermal and SC thickness; *** <span class="html-italic">p</span> ˂ 0.001 vs. vehicle; <sup><span>$</span><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.01 vs. Th2. (<b>C</b>) Quantitative RT-PCR analysis of K10, CASP14, FLG, LOR, and IVL, performed on 3D HEEs and HEEs treated with Th2 cytokines and tofacitinib. All values of mRNA expression were normalized against the expression of GAPDH and were expressed relative to vehicle (taken as 1). Data represented the mean ± SD of three independent experiments; * <span class="html-italic">p</span> ˂ 0.05 vs. vehicle; <sup><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.05 vs. Th2. (<b>D</b>) Western blot analysis of K10, FLG, LOR, and IVL protein expression performed on 3D HEEs and Th2-HEEs treated with tofacitinib. Representative blots are shown. GAPDH was used as endogenous loading control. Densitometric scanning of band intensities was performed to quantify the change in protein expression. Results were expressed as the fold change respect to vehicle (taken as 1-fold). Data represented the mean ± SD of three independent experiments; * <span class="html-italic">p</span> ˂ 0.05 vs. vehicle; <sup><span>$</span><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.01 vs. Th2. (<b>E</b>) Immunofluorescence and (<b>F</b>) quantitative analyses of FLG (green), LOR (red), and IVL (red); * <span class="html-italic">p</span> ˂ 0.05 vs. vehicle; <sup><span>$</span><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.01 vs. Th2, and of (<b>G</b>) pro-FLG and FLG on stratum granulosum and stratum corneum, respectively on serial sections of 3D HEEs and HEEs treated with tofacitinib and Th2 cytokines; * <span class="html-italic">p</span> ˂ 0.05 and *** <span class="html-italic">p</span> ˂ 0.001 vs. vehicle; <sup><span>$</span></sup> <span class="html-italic">p ˂</span> 0.05 vs. Th2. Nuclei were counterstained with DAPI (blue). Scale bar: 50 µm.</p>
Full article ">Figure 2
<p>Effects of JAK/STAT inhibition by tofacitinib on the Th2-mediated changes in the expression of inflammatory and lipid genes. Quantitative RT-PCR analysis of (<b>A</b>) <span class="html-italic">IL-1α</span>, <span class="html-italic">IL-1β</span>, <span class="html-italic">IL-6</span>, <span class="html-italic">IL-8</span>, <span class="html-italic">CCL26</span>, and <span class="html-italic">PDPN</span> (<b>B</b>) <span class="html-italic">ELOVL1</span>, <span class="html-italic">ELOVL3</span>, and <span class="html-italic">ELOVL4</span>, performed on 3D HEEs and Th2-HEEs treated with tofacitinib. All values of mRNA expression were normalized against the expression of <span class="html-italic">GAPDH</span> and were expressed relative to vehicle (taken as 1). Data represented the mean ± SD of three independent experiments; * <span class="html-italic">p</span> ˂ 0.05, ** <span class="html-italic">p</span> ˂ 0.01 vs. vehicle; <sup><span>$</span></sup> <span class="html-italic">p</span> ˂0.05, <sup><span>$</span><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.01 vs. Th2. (<b>C</b>) Western blot analysis of ELOV1 protein expression performed on 3D HEEs and Th2-HEEs treated with tofacitinib. Representative blots are shown. GAPDH was used as the loading control. Densitometric scanning of band intensities was performed to quantify the change in protein expression. Results were expressed as the fold change respect to vehicle (taken as 1-fold). Data represented the mean ± SD of three independent experiments; * <span class="html-italic">p</span> ˂ 0.05 vs. vehicle; <sup><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.05 vs. Th2; (<b>D</b>) Immunohistochemical and (<b>E</b>) quantitative analyses of ELOVL1 on 3D HEEs and Th2-HEEs treated with tofacitinib. Nuclei were counterstained with hematoxylin. Scale bars: 20 µm, 10 µm. ** <span class="html-italic">p</span> ˂ 0.01 vs. vehicle; <sup><span>$</span><span>$</span></sup> <span class="html-italic">p</span> ˂0.01 vs. Th2. (<b>F</b>) Quantitative RT-PCR analysis of <span class="html-italic">SPT</span>, <span class="html-italic">DEGS2</span>, <span class="html-italic">CA2</span>, and <span class="html-italic">PPARγ</span>, performed on 3D HEEs and Th2-HEEs treated with tofacitinib. All values of mRNA expression were normalized against the expression of <span class="html-italic">GAPDH</span> and were expressed relative to vehicle (taken as 1). Data represented the mean ± SD of three independent experiments; * <span class="html-italic">p</span> ˂ 0.05, ** <span class="html-italic">p</span> ˂ 0.01 vs. vehicle; <sup><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.05, <sup><span>$</span><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.01 vs. Th2.</p>
Full article ">Figure 3
<p>Th2 cytokines IL-4 and IL-13 induce lipid changes through the activation of JAK/STAT pathway. (<b>A</b>) Hierarchical clustering of 51 lipid species resulted significantly modulated in the one-way ANOVA applied to the amounts of the 300 characterized lipids. (<b>B</b>) Ultra-long chain SFAs determined by LCMS. Profiles of abundance of (<b>C</b>) PCs determined by HILIC-MS and of (<b>D</b>) Palmitoleic acid (FA 16:1n-7) determined by GCMS and TGs determined by RP-LCMS in lipid extracts of 3D HEEs treated with vehicle, tofacitinib, Th2 cytokines, and combined tofacitinib and Th2 cytokines. Molar amounts of individual lipids were calculated against same-class deuterated internal standards and were normalized by the protein concentration and expressed as pmol/mg protein. Real Time RT-PCR analysis of (<b>E</b>) <span class="html-italic">PLIN1</span> and <span class="html-italic">PLIN2</span>, (<b>F</b>) <span class="html-italic">CPT1α</span>, <span class="html-italic">ACAT1</span>, <span class="html-italic">ACADS</span>, and <span class="html-italic">ACOX1</span>, performed on 3D HEEs and HEEs treated with Th2 cytokines and tofacitinib. All values of mRNA expression were normalized against the expression of <span class="html-italic">GAPDH</span> and were expressed as relative to the vehicle (taken as 1). Data represented the mean ± SD of three independent experiments; * <span class="html-italic">p</span> ˂ 0.05, ** <span class="html-italic">p</span> ˂ 0.01 vs. vehicle; <sup><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.05, <sup><span>$</span><span>$</span></sup> <span class="html-italic">p</span> ˂ 0.01 vs. Th2.</p>
Full article ">Figure 4
<p>Effect of Th2 cytokines and tofacitinib on JAK/STAT signaling. (<b>A</b>) After stimulation with Th2 cytokines (IL-4 and IL-13), activated JAK phosphorylates STATs, which dimerize and translocate to the nucleus. Upon binding to DNA, STATs regulate the transcription of selected genes involved in keratinocyte differentiation, inflammation, and lipid metabolism. As a result, lipid profiles are altered, and the epidermis becomes thicker due to an increase of the space between adjacent keratinocytes. (<b>B</b>) Tofacitinib suppresses STAT phosphorylation through JAK inhibition, counteracting Th2-dependent alterations. PM: plasma membrane; SC: stratum corneum; SG: stratum granulosum; SS: stratum spinosum; SB: stratum basale.</p>
Full article ">
5 pages, 1695 KiB  
Case Report
Intratarsal Keratinous Cyst Clinically Misdiagnosed as a Chalazion
by John Lennon Silva Cunha, Clenia E. S. Andrade, Fernando A. P. da Cunha Filho, Alexandre R. da Paz, Manuel A. Gordón-Núñez, Pollianna M. Alves and Cassiano F. W. Nonaka
Dermatopathology 2024, 11(2), 142-146; https://doi.org/10.3390/dermatopathology11020014 - 19 Apr 2024
Viewed by 1578
Abstract
The intratarsal keratinous cyst (IKC) is a recently described entity, often clinically misdiagnosed as a chalazion. We report a case of a 61-year-old male patient with a chief complaint of a small lesion on the upper eyelid that evolved over six months. On [...] Read more.
The intratarsal keratinous cyst (IKC) is a recently described entity, often clinically misdiagnosed as a chalazion. We report a case of a 61-year-old male patient with a chief complaint of a small lesion on the upper eyelid that evolved over six months. On physical examination, an asymptomatic, firm nodule was identified on the left upper eyelid. The patient reported no history of trauma. A provisional diagnosis of chalazion was established, and an excisional biopsy was performed. Histopathologically, the lesion was lined with a stratified squamous epithelium, with a corrugated epithelial surface showing abrupt keratinization without keratohyalin granules, and compact keratinous-appearing material in the cystic lumen. The diagnosis was IKC. No signs of recurrence were observed after one year of follow-up. It is essential to accurately diagnose IKC and distinguish it from chalazion and epidermal inclusion cysts, because IKC requires complete surgical excision and can exhibit multiple recurrences if not properly removed. Full article
(This article belongs to the Special Issue Educational Case Reports in Dermatopathology)
Show Figures

Figure 1

Figure 1
<p>Clinical aspects of the intratarsal keratinous cyst. (<b>A</b>) Observe a well-delimited small nodular sessile lesion with a reddish color on the left upper eyelid. (<b>B</b>) Clinical appearance one year after lesion removal.</p>
Full article ">Figure 2
<p>Histopathological aspects of the intratarsal keratinous cyst. (<b>A</b>,<b>B</b>) The cyst was lined with a keratinized squamous epithelium, composed of four–five layers of polygonal keratinocytes with a corrugated epithelial surface showing abrupt keratinization without keratohyalin granules. The epithelium–connective tissue interface was flat, and the cystic lumen was filled with abundant, eosinophilic, refractile, and string-like keratin. The cystic capsule was composed of poorly vascularized, tightly woven bundles of tarsal collagen with no evident inflammatory infiltrate. (<b>C</b>) Detail of the cystic epithelial lining displaying parakeratinized stratified squamous epithelium with a corrugated surface (hematoxylin and eosin stain).</p>
Full article ">
Back to TopTop